Effect of Agomelatin on Rat Model of Parkinson's Disease

Basit Öğe Kaydı
dc.contributor.authorAyvat, Pinar
dc.contributor.authorSahin, Aye Saide
dc.contributor.authorSoner, Burak Cem
dc.date.accessioned2024-02-23T14:41:22Z
dc.date.available2024-02-23T14:41:22Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractObjective: Parkinson's disease is one of the most frequently seen neurodegenerative disorders. A definite cure for this disease is not available yet. Agomelatin is the synthetic analog of melatonin hormone that is synthesized in, and released from the pineal gland . Agomelatin shows its antidepressant effects on central nervous system (CNS) by activating melatonin receptors MT1 and MT2 and antagonizing serotonin 5-HT2C receptors stimulated by monoamine transmitters. In this study, we examined the effects of oral agomelatin administration on Parkinson disease-induced experimental rats by using 6-OHDA. Methods: We administered unilateral intrastriatal 6-OHDA to 45 rats weighing 270-330 gr, in three different groups. We applied dissolver on control group; in other two groups we administered agomelatin at daily doses of 5 mg/kg and 20 mg/kg, respectively, for 15 days. At the end of this treatment process, motor coordination and skills were tested with sticky band test, open-field test and cylinder test, whereas, the severity of dopaminergic damage was tested with apomorphine induced rotation test. Results: in our study, we found out that in both doses of agomelatin (5 mg/kg/day and 20 mg/kg/day respectively), prevented progression of experimental Parkinson disease induced with 6-OHDA in rats. Conclusion: Agomelatin protected striatal neurons from destructive effects in experimental Parkinson's Disease model.en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of the University of Ne [151218009]en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of the University of Ne 151218009.en_US
dc.identifier.doi10.5222/buchd.2019.81084
dc.identifier.endpage222en_US
dc.identifier.issn2146-2372
dc.identifier.issn1309-9566
dc.identifier.issue3en_US
dc.identifier.startpage216en_US
dc.identifier.urihttps://doi.org/10.5222/buchd.2019.81084
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16829
dc.identifier.volume9en_US
dc.identifier.wosWOS:000501578900008en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherDr Behcet Uz Cocuk Hastaliklari Ve Cerrahisien_US
dc.relation.ispartofIzmir Dr Behcet Uz Cocuk Hastanesi Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAgomelatinen_US
dc.subjectMelatoninen_US
dc.subjectParkinson's Diseaseen_US
dc.subjectAntidepressanten_US
dc.subjectRaten_US
dc.titleEffect of Agomelatin on Rat Model of Parkinson's Diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu